Compare Samsara Inc (IOT) vs 10X Genomics Inc (TXG) Price & Performance

Samsara (IOT) trades at $38.55, up 0.6% with strong technical momentum and bullish analyst sentiment. The stock shows robust earnings momentum with three consecutive quarterly beats, while revenue growth accelerated to $1.7B in 2026 with positive net income of $58M. Technical indicators show bullish moving averages despite overbought RSI readings, with key resistance at $39-$41. Recent product launches including AI agentic tools and tracking labels demonstrate continued innovation in connected operations.

The outlook remains positive with 78% analyst buy ratings and $44.40 consensus target offering 15% upside. However, elevated valuations (P/E 383) and negative 2025 cash flow (-$59M) present risks. Growth sustainability depends on maintaining large customer momentum and margin expansion amid AI investments. The stock presents a growth opportunity but requires monitoring of execution and valuation compression risks.

TXG trades at $43.18, down 1.28% today, with a bullish technical signal and positive earnings momentum. The stock shows improving fundamentals with revenue growth to $642.82M in 2025 and narrowing losses, while maintaining a strong gross margin of 69.6%. Recent acquisitions and partnerships with Cleveland Clinic demonstrate strategic expansion in genomic diagnostics.

The outlook remains cautiously optimistic with analyst consensus at Buy (45%) and price target of $39.14. Key risks include continued negative profitability metrics and high valuation multiples, while catalysts include upcoming Q2 2026 earnings and platform adoption growth.